AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK pricing regulator for their breast cancer therapy Enhertu, Bloomberg reported. The development suggests a path to pricing clarity in the UK market, which can support revenue visibility for the product, though no financial terms were disclosed.
AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK pricing regulator for their breast cancer therapy Enhertu, Bloomberg reported. The development suggests a path to pricing clarity in the UK market, which can support revenue visibility for the product, though no financial terms were disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
